Molecular Pathology of
Bladder Cancer
Bladder Cancer
|
Molecular Pathology of Bladder Cancer |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Region | Incidence Overall | Incidence Males | Incidence Females | Deaths Overall | Deaths Males | Deaths Females |
|---|---|---|---|---|---|---|
| USA | 70530 | 52760 | 17770 | 14680 | 10410 | 4270 |
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKT1 | PI3-Kinase Signaling |
2.7% | ||||||||||
| ErbB-2 (Her2/neu) | Receptor Tyrosine Kinase Signaling |
transitional cell carcinoma (TCC) of urinary bladder | 6% | |||||||||
| ErbB-2 (Her2/neu) | Receptor Tyrosine Kinase Signaling |
transitional cell carcinoma (TCC) of urinary bladder | 60% | protein overexpression by IHC | ||||||||
| FGFR-3 | 36 - 54% | more frequent in low grade tumors | ||||||||||
| HRAS (H-Ras Farnesyl-Transferase) | 4% | |||||||||||
| KRAS | Ras Signal Transduction Pathway |
7% | ||||||||||
| p14ARF (CDKN2A) | p53 Tumor Suppressor Pathway |
transitional cell carcinoma | 43% | |||||||||
| p16INK4a (CDKN2A) | Cell Cycle Regulation |
transitional cell carcinoma | 23% | |||||||||
| p16INK4a (CDKN2A) | Cell Cycle Regulation |
transitional cell carcinoma | 60% | |||||||||
| Pi3-kinase | PI3-Kinase Signaling |
13 - 27% | associated with low-grade tumors: | |||||||||
| PTEN | PI3-Kinase Signaling |
8% | absence of expression | |||||||||
| TSC1 | PI3-Kinase Signaling |
16% |
| See Clinical Trials in in the TTC Database |
| CANCER.GOV PDQ® - Standard Treatments for Bladder Cancer |